Heartflow, Inc. (NASDAQ:HTFL – Get Free Report) has received an average recommendation of “Moderate Buy” from the ten brokerages that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation, six have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $37.00.
HTFL has been the subject of a number of recent research reports. William Blair initiated coverage on shares of Heartflow in a report on Monday, May 4th. They issued an “outperform” rating for the company. Freedom Capital upgraded shares of Heartflow to a “strong-buy” rating in a report on Tuesday, June 30th. Weiss Ratings raised shares of Heartflow from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, June 12th. Piper Sandler reissued an “overweight” rating on shares of Heartflow in a research report on Thursday, June 11th. Finally, JPMorgan Chase & Co. lowered their target price on shares of Heartflow from $40.00 to $35.00 and set an “overweight” rating for the company in a research note on Thursday, March 19th.
Check Out Our Latest Analysis on HTFL
Heartflow Stock Performance
Heartflow (NASDAQ:HTFL – Get Free Report) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.08. The company had revenue of $52.59 million during the quarter. Heartflow’s revenue for the quarter was up 41.3% compared to the same quarter last year. On average, equities analysts predict that Heartflow will post -0.82 earnings per share for the current fiscal year.
Insider Activity
In other news, CEO John C.M. Farquhar sold 38,900 shares of the firm’s stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $35.00, for a total value of $1,361,500.00. Following the completion of the sale, the chief executive officer owned 457,935 shares of the company’s stock, valued at $16,027,725. This trade represents a 7.83% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Bain Capital Life Sciences Inv sold 948,757 shares of the business’s stock in a transaction on Thursday, April 30th. The stock was sold at an average price of $29.23, for a total value of $27,732,167.11. Following the transaction, the insider owned 8,448,158 shares in the company, valued at approximately $246,939,658.34. This trade represents a 10.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 2,115,805 shares of company stock worth $62,422,505. Insiders own 7.70% of the company’s stock.
Hedge Funds Weigh In On Heartflow
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Wellington Management Group LLP grew its position in Heartflow by 20.8% during the 4th quarter. Wellington Management Group LLP now owns 5,894,070 shares of the company’s stock worth $171,812,000 after purchasing an additional 1,014,006 shares during the last quarter. Bamco Inc. NY raised its holdings in shares of Heartflow by 86.2% in the fourth quarter. Bamco Inc. NY now owns 2,303,877 shares of the company’s stock worth $67,158,000 after buying an additional 1,066,371 shares during the last quarter. Janus Henderson Group PLC lifted its stake in shares of Heartflow by 152.0% during the first quarter. Janus Henderson Group PLC now owns 2,180,976 shares of the company’s stock worth $53,063,000 after buying an additional 1,315,416 shares during the period. Schusterman Interests LLC purchased a new stake in shares of Heartflow during the third quarter valued at $65,274,000. Finally, Capricorn Investment Group LLC acquired a new position in shares of Heartflow in the 4th quarter valued at $48,178,000.
Heartflow Company Profile
HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.
HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.
Featured Articles
- Five stocks we like better than Heartflow
- Visa’s Open USD Push Puts Circle’s Stablecoin Moat Under Pressure
- This Under-the-Radar Industrial Is Quietly Powering AI
- Why Microsoft Looks Like the Best Big Tech Trade for H2 2026
- Strategy’s Bitcoin Pivot Gives Investors a New Reason to Watch Preferred Shares
Receive News & Ratings for Heartflow Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heartflow and related companies with MarketBeat.com's FREE daily email newsletter.
